pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Sep 1·1 min read
save

Trump announces voluntary pricing agreements with nine new drug makers

Sep 1, 2026·read at Endpoints ↗RegulatoryNeutral

President Donald Trump hosted a drug pricing event on Monday, joined by executives from several pharmaceutical companies and senior health officials.

At the meeting he announced voluntary pricing deals with nine new companies, marking the first time the administration has extended such agreements beyond the original group of firms targeted in earlier letters.

The expansion suggests a broader, collaborative approach to drug pricing, though the specific terms of the agreements were not disclosed.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Three takeaways from Trump's latest drug pricing event”

read at Endpoints ↗
102 words · retrieved Sep 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 12h agoMerck reports mixed data for Lucentis competitor in diabetic macular edemaEndpoints
  • 13h agoAsahi Kasei lands approval for new HSV treatmentEndpoints
  • 15h agoMirum succeeds in rare liver disease trial; First Tracks delivers in celiacEndpoints
  • 15h agoBristol Myers reveals a pair of Phase 3 wins for fibrosis, RayzeBio drugsEndpoints
  • 15h agoBrent Saunders out as Bausch + Lomb CEO, an abrupt end to three-year runEndpoints